School of Pharmacy, Shenyang Pharmaceutical University, Shenyang 110016, China.
School of Pharmacy, Shenyang Pharmaceutical University, Shenyang 110016, China.
J Control Release. 2023 Sep;361:191-211. doi: 10.1016/j.jconrel.2023.07.055. Epub 2023 Aug 5.
Posterior segment diseases, such as age-related macular degeneration (AMD) and diabetic retinopathy (DR) are vital factor that seriously threatens human vision health and quality of life, the treatment of which poses a great challenge to ophthalmologists and ophthalmic scientists. In particular, ocular posterior drug delivery in a non-invasive manner is highly desired but still faces many difficulties such as rapid drug clearance, limited permeability and low drug accumulation at the target site. At present, many novel non-invasive topical ocular drug delivery systems are under development aiming to improve drug delivery efficiency and biocompatibility for better therapy of posterior segment oculopathy. The purpose of this review is to present the challenges in the noninvasive treatment of posterior segment diseases, and to propose strategies to tackle these bottlenecks. First of all, barriers to ocular administration were introduced based on ocular physiological structure and behavior, including analysis and discussion on the influence of ocular structures on noninvasive posterior segment delivery. Thereafter, various routes of posterior drug delivery, both invasive and noninvasive, were illustrated, along with the respective anatomical obstacles that need to be overcome. The widespread and risky application of invasive drug delivery, and the need to develop non-invasive local drug delivery with alternative to injectable therapy were described. Absorption routes through topical administration and strategies to enhance ocular posterior drug delivery were then discussed. As a follow-up, an up-to-date research advances in non-invasive delivery systems for the therapy of ocular fundus lesions were presented, including different nanocarriers, contact lenses, and several other carriers. In conclusion, it seems feasible and promising to treat posterior oculopathy via non-invasive local preparations or in combination with appropriate devices.
后节疾病,如年龄相关性黄斑变性(AMD)和糖尿病性视网膜病变(DR),是严重威胁人类视力健康和生活质量的重要因素,其治疗对眼科医生和眼科科学家构成了巨大挑战。特别是以非侵入性方式向眼部后节递药,高度期望,但仍然面临许多困难,如药物快速清除、有限的通透性和目标部位的药物蓄积低。目前,许多新型非侵入性局部眼部药物递送系统正在开发中,旨在提高药物递送效率和生物相容性,以更好地治疗后节眼病。本综述的目的是提出后节疾病非侵入性治疗的挑战,并提出解决这些瓶颈的策略。首先,根据眼部生理结构和行为介绍了眼部给药的障碍,包括对眼部结构对非侵入性后节递药的影响进行分析和讨论。此后,说明了各种侵袭性和非侵袭性的后节药物递送途径,以及需要克服的各自的解剖学障碍。描述了侵袭性药物递送的广泛和高风险应用,以及开发替代注射治疗的非侵入性局部药物递送的必要性。然后讨论了通过局部给药的吸收途径和增强眼部后节药物递送的策略。随后,介绍了眼部眼底病变治疗的非侵入性递药系统的最新研究进展,包括不同的纳米载体、隐形眼镜和其他几种载体。总之,通过非侵入性局部制剂或与适当的装置联合治疗后节眼病似乎是可行和有前途的。